Published in Osteoporos Int on October 20, 2010
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ (2010) 6.37
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
Pitfalls in the external validation of FRAX. Osteoporos Int (2011) 2.21
Genetic determinants of trabecular and cortical volumetric bone mineral densities and bone microstructure. PLoS Genet (2013) 1.64
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int (2012) 1.36
Lumbar spine bone mineral density in US adults: demographic patterns and relationship with femur neck skeletal status. Osteoporos Int (2011) 1.20
Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. Can Assoc Radiol J (2011) 1.11
Comparison between various fracture risk assessment tools. Osteoporos Int (2014) 1.00
Reference values of bone mineral density and prevalence of osteoporosis in Chinese adults. Osteoporos Int (2013) 1.00
A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos (2016) 0.92
FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort. BMC Musculoskelet Disord (2012) 0.87
Health technology assessment in osteoporosis. Calcif Tissue Int (2013) 0.85
What was your fracture risk evaluated by FRAX® the day before your osteoporotic fracture? Clin Rheumatol (2012) 0.82
Screening: FRAX in clinical practice. Nat Rev Rheumatol (2011) 0.79
A comparative study of using non-hip bone density inputs with FRAX®. Osteoporos Int (2011) 0.79
Potential Extensions of the US FRAX Algorithm. J Osteoporos (2012) 0.78
Waning predictive value of serum adiponectin for fracture risk in elderly men: MrOS Sweden. Osteoporos Int (2014) 0.78
Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tissue Int (2014) 0.76
Were you identified to be at high fracture risk by FRAX® before your osteoporotic fracture occurred? Clin Rheumatol (2014) 0.75
Number of osteoporotic sites as a modifying factor for bone mineral density. J Bone Miner Metab (2014) 0.75
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Assessment of fracture risk. Osteoporos Int (2004) 5.15
Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med (2008) 5.05
A reference standard for the description of osteoporosis. Bone (2007) 3.67
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J (2005) 2.15
Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system. J Bone Miner Res (2011) 1.68
Discordance in patient classification using T-scores. J Clin Densitom (1999) 1.46
Validation of an electronic, population-based prescription database. Ann Pharmacother (1998) 1.45
Identification and validation of vertebral compression fractures using administrative claims data. Med Care (2009) 1.45
Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab (2006) 1.39
The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int (2009) 1.36
The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int (2006) 1.31
Construction and validation of a population-based bone densitometry database. J Clin Densitom (2005) 1.24
Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care (1999) 1.07
Single-site vs multisite bone density measurement for fracture prediction. Arch Intern Med (2007) 1.02
Recalculation of the NHANES database SD improves T-score agreement and reduces osteoporosis prevalence. J Bone Miner Res (2004) 1.00
Interobserver reproducibility of criteria for vertebral body exclusion. J Bone Miner Res (2004) 0.98
A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service. Osteoporos Int (2004) 0.90
Does the combination of two BMD measurements improve fracture discrimination? J Bone Miner Res (2003) 0.86
The importance of spectrum bias on bone density monitoring in clinical practice. Bone (2006) 0.86
Simplified 10-year absolute fracture risk assessment: a comparison of men and women. J Clin Densitom (2010) 0.84
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05
FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75
World-wide projections for hip fracture. Osteoporos Int (1997) 6.83
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int (2004) 4.24
Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst (1995) 3.79
Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Bone densitometry in clinical practice. BMJ (1995) 3.48
Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int (2001) 3.23
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08
Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int (2011) 3.04
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int (2000) 2.99
The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int (2001) 2.81
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet (2002) 2.76
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
A global representation of vitamin D status in healthy populations. Arch Osteoporos (2012) 2.69
The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int (1993) 2.66
The components of excess mortality after hip fracture. Bone (2003) 2.63
Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer (1998) 2.51
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43
The surgeon as a prognostic factor after the introduction of total mesorectal excision in the treatment of rectal cancer. Br J Surg (2002) 2.41
Bone-density measurement. Lancet (1992) 2.38
Influence of hospital- and surgeon-related factors on outcome after treatment of rectal cancer with or without preoperative radiotherapy. Br J Surg (1997) 2.21
Pitfalls in the external validation of FRAX. Osteoporos Int (2011) 2.21
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ (1995) 2.10
Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys (1992) 2.09
Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04
Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol (2010) 2.02
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat (2009) 1.90
Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone (2000) 1.89
Long-term follow-up of patients with untreated scoliosis. A study of mortality, causes of death, and symptoms. Spine (Phila Pa 1976) (1992) 1.88
Risk of vertebral fracture in women with rheumatoid arthritis. BMJ (1993) 1.87
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Treatment failure in osteoporosis. Osteoporos Int (2012) 1.82
The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int (1992) 1.81
Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res (1995) 1.79
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77
The risk and burden of vertebral fractures in Sweden. Osteoporos Int (2003) 1.74
Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer (1990) 1.73
Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke (2001) 1.73
Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos (2013) 1.72
Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J (2007) 1.71
A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int (2002) 1.70
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br J Surg (2005) 1.68
Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet (1980) 1.68
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives. Br Med J (1977) 1.62
The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer (1995) 1.60
The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol (1999) 1.60
Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int (1999) 1.59
Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int (2012) 1.58
Position sense acuity is diminished following repetitive low-intensity work to fatigue in a simulated occupational setting. Eur J Appl Physiol (2000) 1.57
Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg (2013) 1.56
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum (1991) 1.56
Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin (2013) 1.55
Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol (1999) 1.53
Estimation of the parenchymal-cell content of the parathyroid gland, using density-gradient columns. Preliminary report. Acta Pathol Microbiol Scand A (1977) 1.52
Is 24,25-dihydroxycholecalciferol a calcium-regulating hormone in man? Br Med J (1978) 1.49
Use of diphosphonates in hypercalcaemia due to malignancy. Lancet (1990) 1.47
Influence of recency and duration of glucocorticoid use on bone mineral density and risk of fractures: population-based cohort study. Osteoporos Int (2013) 1.46
Spinal cord dysfunction in Paget's disease of bone. Has medical treatment a vascular basis? J Bone Joint Surg Br (1981) 1.46
The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int (1994) 1.46
The excess mortality due to periprosthetic femur fracture. A study from the Swedish national hip arthroplasty register. Bone (2007) 1.46
Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int (2010) 1.46